We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
![Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations](https://www.ohe.org/wp-content/uploads/2023/01/Healthcare-systems_AdobeStock_Rawpixel.com_landscape.jpg)
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
![Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies](https://www.ohe.org/wp-content/uploads/2020/08/Bridge-150x150.png)
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
![WHO-cancer-medicines-rebrand](https://www.ohe.org/wp-content/uploads/2019/05/WHO-cancer-medicines-rebrand.png)
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
![Quality of Life in Long-term Cancer Cover Page](https://www.ohe.org/wp-content/uploads/2018/06/Quality-of-Life-in-Long-term-Cancer-Cover-Page_0.jpg)
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
![Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover](https://www.ohe.org/wp-content/uploads/2016/12/MCDA-Front-Cover.jpg)